About Brain Vectis
Brain Vectis is a Healthcare company based in Paris (France) founded in 2015, and was acquired by AskBio in April 2020. Brain Vectis has raised $1.1 million across 1 funding round from investors including AskBio. The company was acqui-hired. Brain Vectis offers products and services including AAV Technology Platform, Capsids, Promoters, Pro10â„¢, and neDNAâ„¢. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is AskBio Inc.
Company details
Developer of gene therapies for the treatment of Alzheimers and Huntingtons disease. It is using AAV to deliver CYP46A1, a key enzyme of brain cholesterol metabolism which is impaired in neurodegenerative diseases. CYP46A1 is reduced in the brain of HD and AD patients. Cholesterol accumulates and the cholesterol pathway is slowed down. CYP46A1 turns the excess cholesterol into a derivative able to move freely from the brain to the blood for peripheral elimination.
- Headquarters Paris, France
- Stage Acquired
- SectorsHealthcare
- Website brainvectis.com
- Social LinkedIn X YouTube
- Acquired by AskBio (Apr 2020)
- Legal Name Askbio Inc.
Products & Services of Brain Vectis
Brain Vectis offers a comprehensive portfolio of products and services, including AAV Technology Platform, Capsids, Promoters, Pro10™, and neDNA™.
Provides tools for developing AAV-based therapies for genetic diseases.
Viral components used to deliver gene therapies to target cells.
Elements that control gene expression in therapy applications.
Advanced promoter system for improved gene therapy efficacy.
Innovative DNA constructs for gene therapy development.
Processes for scalable production of gene therapy products.
Apps and channels of Brain Vectis
its YouTube channel AskBio Inc. has 86 subscribers and 7 videos.
Videos from Brain Vectis
The most watched videos on Brain Vectis's YouTube channel, AskBio Inc. (86 subscribers). Click a video to play it here.
More on AskBio Inc..
Funding Insights of Brain Vectis
Brain Vectis has successfully raised a total of $1.1M through 1 strategic funding round. The most recent funding activity was a Series A round of $1.1 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.1M
- Total Rounds 1
- Last Round Series A — $1.1M
- First Round $1.1M
(Sep 2016)
All 1 funding rounds of Brain Vectis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2016 | $1.1M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Brain Vectis
Brain Vectis has secured backing from 1 investor. Prominent investors backing the company include AskBio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Gene and protein therapies are developed for treating various diseases. | 2001 | askbio.com | Durham, United States |
Investor details for Brain Vectis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Brain Vectis
3 dated milestones of Brain Vectis across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Brain Vectis is founded.
- Funding First funding round of $1.1M.
- Exit Acquired by AskBio.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Brain Vectis
Complete news archive for Brain Vectis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Brain Vectis
Brain Vectis was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Brain Vectis is headquartered in Paris, France.
Brain Vectis is a funded company, having raised a total of $1.1M across 1 funding round to date. The company's 1st funding round was a Series A of $1.1M, raised on Sep 2016.
Developer of gene therapies for the treatment of Alzheimers and Huntingtons disease. It is using AAV to deliver CYP46A1, a key enzyme of brain cholesterol metabolism which is impaired in neurodegenerative diseases. CYP46A1 is reduced in the brain of HD and AD patients. Cholesterol accumulates and the cholesterol pathway is slowed down. CYP46A1 turns the excess cholesterol into a derivative able to move freely from the brain to the blood for peripheral elimination.
Brain Vectis offers AAV Technology Platform, Capsids, Promoters, Pro10â„¢, and 2 more products and services.
Brain Vectis has 1 investor. Key investors include AskBio.
Brain Vectis operates through Askbio Inc..
Yes. Brain Vectis was acquired by AskBio in April 2020.